My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Pralatrexate (racemic)
    Pralatrexate (racemic)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0848
    CAS #: 146464-95-1 Purity ≥98%

    Description: Pralatrexate (PDX; trade name Folotyn), an antifolate which is structurally a folate analog, is a potent and selective inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate has been approved by FDA to treat a certain type of cancer called peripheral T-Cell lymphoma-PTCL.

    References: Clin Cancer Res. 2010 Jul 15;16(14):3648-58; Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9. 

    Related CAS: 146464-95-1 (racemic); 1320211-69-5 (S-isomer); 1320211-70-8 (R-isomer)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)477.47
    CAS No.146464-95-1(racemic); 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 28 mg/mL (58.6 mM)
    Water: <1 mg/mL
    Ethanol: <1 mg/mL
    Other info
    Chemical Name: N -(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid
    InChi Code: InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1
    SMILES Code: O=C(O)CC[[email protected]@H](C(O)=O)NC(C1=CC=C(C(CC2=NC3=C(N)N=C(N)N=C3N=C2)CC#C)C=C1)=O 
    SynonymsPDX; Pralatrexate; 10-Propargyl-10-deazaaminopterin; trade name: Folotyn. 

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Pralatrexate and bortezomib exhibits concentration- and time-dependent cytotoxicity against a broad panel of T-lymphoma cell lines. Pralatrexate shows synergism when combined with bortezomib in all cell lines studied. Pralatrexate also induces potent apoptosis and caspase activation when combined with bortezomib across the panel. Pralatrexate significantly modulates the expression of p27, NOXA, HH3, and RFC-1 as assessed by Western blot assays. Pralatrexate is rationally designed for improved cellular transport via RFC-1, and to have greater intracellular drug retention through the enhanced formation of polyglutamylated conjugates. Pralatrexate is thought to exert its pharmacological effect primarily through inhibition of DHFR, having an IC50 in the picomolar range. Pralatrexate demonstrates superior intracellular transport via the reduced folate carrier, and increased accumulation within cells by enhanced polyglutamylation. Pralatrexate exhibits antitumor activity that is superior to the activity of other antifolates. Pralatrexate's enhanced activity relative to methotrexate (MTX) is due to its much more rapid rate of transport and polyglutamation, the former less important when the carrier is saturated

    Cell Assay: Pralatrexate(Folotyn) is an antifolate, and structurally a folate analog. Its IC50 is < 300 nM in some cell lines. Based on preclinical studies, researchers believe that Pralatrexate selectively enters cells expressing reduced folate carrier type 1 (RFC-1), a protein that is overexpressed on certain cancer cells compared to normal cells. 

    In VivoPralatrexate treatment results in treatment-related toxicity in MV522 mice models, as determined by significant weight loss in some animals prior to death; however, remaining mice regains all lost weight by Day 35.
    Animal modelMV522 mice
    Formulation & DosageN/A
    ReferencesClin Cancer Res. 2010 Jul 15;16(14):3648-58; Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    A short-term uptake of radiolabeled antifolates in NCI-H460 cells Drugs were dosed for 15 or 60 min. White bars cells incubated with radiolabeled drug only, black bars cells incubated with radiolabeled drug plus excess unlabeled drug. Cancer Chemother Pharmacol.2009 Oct;64(5):993-9.
    Differential activity of the antifolates on tumor volume and body weight in NCI-H460 and MV522 human tumor xenografts. Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9.
    Inhibition of DHFR activity by pralatrexate in a cell-free system. Cancer Chemother Pharmacol. 2009 Oct;64(5):993-9. 


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?